is everyone on a glp 1 Should be GLP-1s? What the science really tells us about cancer prevention and other benefits “Everyone Should be on a

Description

Loureno et al

Liraglutide and semaglutide have beneficial effects on non-alcoholic steatohepatitis.200,201 Additionally, incretin mimetic drugs targeting multiple receptors for greater efficacy, including glucagon and GIP receptors, are under development.202 A Phase 2a study of efocipegtrutide (HM15211), a new long-acting triple GLP-1/GIP/glucagon RA is currently being conducted to assess its use to treat non-alcoholic steatohepatitis.203 Survodutide, a novel dual GLP-1/ glucagon RA, significantly reduced body weight and improved metabolic dysfunction-associated steatohepatitis compared to the placebo in phase II trials.204 Mazdutide, a dual GLP-1/glucagon RA, and retatrutide, a triple GLP-1/GIP/glucagon RA, also have both shown significant weight loss effects in Phase 2 trials.205,206 Among the drugs discussed, including US FDA-approved GLP-1 RAs, tirzepatide was reported to achieve the most significant reduction in blood glucose levels

Notable legal actions involving Zepbound and related issues include: Patients who experience serious complications after taking Zepbound for weight loss may be eligible to join the MDL against Eli Lilly, while other lawsuits continue to address antitrust, insurance coverage, and marketing conduct concerns

Acute administration of the GLP-1RA exenatide resulted in reduced feelings of hunger, which is due to an increase in functional connectivity of the nucleus tractus solitarius with the hypothalamus and thalamus [129]